Daxor Corp
DXR
Company Profile
Business description
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
Contact
107 Meco Lane
Oak RidgeTN37830
USAT: +1 212 330-8500
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
750
Stocks News & Analysis
stocks
This onetime AI market darling is now surprisingly undervalued
This AI leader qualifies as a GARP stock today.
stocks
Undervalued ASX miner hits production homerun
Record volumes, lower costs and reduced debt underpin a stronger earnings outlook for ASX miner.
stocks
Meta earnings: AI-driven improvements in top line fail to impress investors
We reiterate our fair value estimate for wide-moat Meta and view the after-market selloff as an overreaction
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,145.30 | 61.90 | -0.67% |
| CAC 40 | 8,485.64 | 77.37 | 0.92% |
| DAX 40 | 25,612.03 | 151.55 | 0.60% |
| Dow JONES (US) | 52,208.06 | 613.92 | 1.19% |
| FTSE 100 | 10,897.27 | 11.14 | -0.10% |
| HKSE | 25,830.58 | 28.30 | -0.11% |
| NASDAQ | 25,122.18 | 679.24 | 2.78% |
| Nikkei 225 | 64,332.07 | 2,464.64 | 3.98% |
| NZX 50 Index | 13,771.26 | 8.48 | 0.06% |
| S&P 500 | 7,437.63 | 121.48 | 1.66% |
| S&P/ASX 200 | 8,985.30 | 64.60 | -0.71% |
| SSE Composite Index | 3,833.65 | 28.96 | 0.76% |